Despite a challenging economic climate in the latter half of 2022, the year was marked by major milestones in psychedelic medicine.
Research is a cumulative process, with subsequent studies building on the success of previous work.
This year that research also instigated regulatory reform, following clinical trials which demonstrated the safety and efficacy of psychedelic-assisted therapy.
READ MORE
The Phase III study is forecast to cost £2.25 million, with the government investing nearly £1.5 million.
Read More
Dr Gerhard Gründer from the Central Institute of Mental Health spoke with Psychedelic Health on the announcement.
Read More86% of bipolar disorder patients enter remission after COMP360 psilocybin therapy.
North American drug developers partner with UK-based Clerkenwell Health.
Psychedelic stocks set to rebound in 2023.
Patent strategies for psilocybin-assisted therapy.
Unregulated psilocybin dispensaries emerging.
Irwin Naturals acquires ketamine clinics in Florida.
Following the success of the SOLD OUT PSYCH Symposium in 2022, the industry-leading conference returns to the iconic British Museum on Thursday, 6 July 2023.
Super Early Bird tickets now on sale for £249 + VAT.
TICKET REGISTRATIONUCL to conduct brain-imaging study at psychedelic retreat.
Psilocybin has limited effect on biomarkers of inflammation.
How ketamine instigates changes in neural activity.
Congress issues directive for psychedelic research.
The research into ketamine-assisted therapy for treatment-resistant depression.
The new fourth edition of The Psychedelics as Medicine Report contains industry intelligence, with an exclusive contribution from Angela Allbee, Psilocybin Services Section Manager at Oregon Health Authority.
COMPLIMENTARY DOWNLOADPAREA appeals to EU institutions to adopt psychedelic healthcare.
An overview of US regulatory reform.
The impact of Colorado’s decriminalisation measure.
Denver District Attorney dismisses case following psilocybin vote.
The need for an overhaul of US drug policy.
State-wide psilocybin reform in North America.
Common DMT entity encounters.
Psilocybin mushroom store opens in Ontario.
One in three UK workers suffers from severe anxiety or depression.